Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
0.9874
-0.0726 (-6.85%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.

Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma.

It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.

Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology, Inc.
Pyxis Oncology logo
Country United States
Founded 2018
IPO Date Oct 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Lara Sullivan

Contact Details

Address:
321 Harrison Avenue, 11th Floor, Suite 1
Boston, Massachusetts 02118
United States
Phone 617 453 3596
Website pyxisoncology.com

Stock Details

Ticker Symbol PYXS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001782223
CUSIP Number 747324101
ISIN Number US7473241013
Employer ID 83-1160910
SIC Code 2834

Key Executives

Name Position
Dr. Lara S. Sullivan M.D., MBA Chief Executive Officer, President, Chief Medical Officer and Director
Pamela Yanchik Connealy M.B.A. Chief Financial Officer and Chief Operating Officer
Jitendra Wadhane Chief Accounting Officer, Senior Vice President of Finance and Corporate Controller
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer
Dr. Jan Pinkas Ph.D. Chief Scientific Officer
Dr. Charles T. Gombar Ph.D. Senior Vice President of Portfolio and Program Management
Stephen T. Worsley MBA Senior Vice President and Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 24, 2025 8-K Current Report
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 4, 2025 SCHEDULE 13G Filing
Feb 4, 2025 8-K Current Report
Dec 23, 2024 SCHEDULE 13D/A Filing